Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus cisplatin and 5-fluorouracil as neoadjuvant therapy for head and neck squamous cell carcinoma
ChiCTR2500099204Phase 2Recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by Dongguan People's Hospital. Primary endpoint: Objective response rate. Started Mar 2025; status: recruiting.
02
Drugs
serplulimabcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500099204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099204.